46 related articles for article (PubMed ID: 16350414)
1. In vitro assays of substrate degradation induced by high-risk HPV E6 oncoproteins.
Thomas M; Banks L
Methods Mol Med; 2005; 119():411-7. PubMed ID: 16350414
[TBL] [Abstract][Full Text] [Related]
2. Comparative analysis of 19 genital human papillomavirus types with regard to p53 degradation, immortalization, phylogeny, and epidemiologic risk classification.
Hiller T; Poppelreuther S; Stubenrauch F; Iftner T
Cancer Epidemiol Biomarkers Prev; 2006 Jul; 15(7):1262-7. PubMed ID: 16835321
[TBL] [Abstract][Full Text] [Related]
3. Involvement of nuclear export in human papillomavirus type 18 E6-mediated ubiquitination and degradation of p53.
Stewart D; Ghosh A; Matlashewski G
J Virol; 2005 Jul; 79(14):8773-83. PubMed ID: 15994771
[TBL] [Abstract][Full Text] [Related]
4. Interaction of HPV E6 oncoproteins with specific proteasomal subunits.
Tomaić V; Ganti K; Pim D; Bauer C; Blattner C; Banks L
Virology; 2013 Nov; 446(1-2):389-96. PubMed ID: 24074603
[TBL] [Abstract][Full Text] [Related]
5. High-risk HPV E6 oncoproteins assemble into large oligomers that allow localization of endogenous species in prototypic HPV-transformed cell lines.
García-Alai MM; Dantur KI; Smal C; Pietrasanta L; de Prat-Gay G
Biochemistry; 2007 Jan; 46(2):341-9. PubMed ID: 17209544
[TBL] [Abstract][Full Text] [Related]
6. Specific HIV protease inhibitors inhibit the ability of HPV16 E6 to degrade p53 and selectively kill E6-dependent cervical carcinoma cells in vitro.
Hampson L; Kitchener HC; Hampson IN
Antivir Ther; 2006; 11(6):813-25. PubMed ID: 17310826
[TBL] [Abstract][Full Text] [Related]
7. HPV E6 proteins interact with specific PML isoforms and allow distinctions to be made between different POD structures.
Guccione E; Lethbridge KJ; Killick N; Leppard KN; Banks L
Oncogene; 2004 Jun; 23(27):4662-72. PubMed ID: 15107834
[TBL] [Abstract][Full Text] [Related]
8. HPV16 E6 natural variants exhibit different activities in functional assays relevant to the carcinogenic potential of E6.
Lichtig H; Algrisi M; Botzer LE; Abadi T; Verbitzky Y; Jackman A; Tommasino M; Zehbe I; Sherman L
Virology; 2006 Jun; 350(1):216-27. PubMed ID: 16519914
[TBL] [Abstract][Full Text] [Related]
9. The high-risk HPV E6 oncoprotein preferentially targets phosphorylated nuclear forms of hDlg.
Narayan N; Subbaiah VK; Banks L
Virology; 2009 Apr; 387(1):1-4. PubMed ID: 19307009
[TBL] [Abstract][Full Text] [Related]
10. Cyclooxygenase-2 transcription is regulated by human papillomavirus 16 E6 and E7 oncoproteins: evidence of a corepressor/coactivator exchange.
Subbaramaiah K; Dannenberg AJ
Cancer Res; 2007 Apr; 67(8):3976-85. PubMed ID: 17440114
[TBL] [Abstract][Full Text] [Related]
11. Isolation and functional analysis of five HPVE6 variants with respect to p53 degradation.
Hiller T; Stubenrauch F; Iftner T
J Med Virol; 2008 Mar; 80(3):478-83. PubMed ID: 18205217
[TBL] [Abstract][Full Text] [Related]
12. A single-codon mutation converts HPV16 E6 oncoprotein into a potential tumor suppressor, which induces p53-dependent senescence of HPV-positive HeLa cervical cancer cells.
Ristriani T; Fournane S; Orfanoudakis G; Travé G; Masson M
Oncogene; 2009 Feb; 28(5):762-72. PubMed ID: 19015633
[TBL] [Abstract][Full Text] [Related]
13. A plant lignan, 3'-O-methyl-nordihydroguaiaretic acid, suppresses papillomavirus E6 protein function, stabilizes p53 protein, and induces apoptosis in cervical tumor cells.
Allen KL; Tschantz DR; Awad KS; Lynch WP; DeLucia AL
Mol Carcinog; 2007 Jul; 46(7):564-75. PubMed ID: 17393435
[TBL] [Abstract][Full Text] [Related]
14. [Virological and carcinogenic aspects of HPV].
Prétet JL; Charlot JF; Mougin C
Bull Acad Natl Med; 2007 Mar; 191(3):611-23; discussion 623. PubMed ID: 18072657
[TBL] [Abstract][Full Text] [Related]
15. Protein intrinsic disorder and human papillomaviruses: increased amount of disorder in E6 and E7 oncoproteins from high risk HPVs.
Uversky VN; Roman A; Oldfield CJ; Dunker AK
J Proteome Res; 2006 Aug; 5(8):1829-42. PubMed ID: 16889404
[TBL] [Abstract][Full Text] [Related]
16. The human papillomavirus (HPV) E6* proteins from high-risk, mucosal HPVs can direct degradation of cellular proteins in the absence of full-length E6 protein.
Pim D; Tomaic V; Banks L
J Virol; 2009 Oct; 83(19):9863-74. PubMed ID: 19640984
[TBL] [Abstract][Full Text] [Related]
17. Activities of human papillomavirus 16 E6 natural variants in human keratinocytes.
Asadurian Y; Kurilin H; Lichtig H; Jackman A; Gonen P; Tommasino M; Zehbe I; Sherman L
J Med Virol; 2007 Nov; 79(11):1751-60. PubMed ID: 17854024
[TBL] [Abstract][Full Text] [Related]
18. Human papillomavirus: E6 and E7 oncogenes.
Boulet G; Horvath C; Vanden Broeck D; Sahebali S; Bogers J
Int J Biochem Cell Biol; 2007; 39(11):2006-11. PubMed ID: 17768080
[TBL] [Abstract][Full Text] [Related]
19. Human telomerase reverse transcriptase activated by E6 oncoprotein is required for human papillomavirus-16/18-infected lung tumorigenesis.
Cheng YW; Wu TC; Chen CY; Chou MC; Ko JL; Lee H
Clin Cancer Res; 2008 Nov; 14(22):7173-9. PubMed ID: 19010833
[TBL] [Abstract][Full Text] [Related]
20. Ubiquitination and proteasome degradation of the E6 proteins of human papillomavirus types 11 and 18.
Stewart D; Kazemi S; Li S; Massimi P; Banks L; Koromilas AE; Matlashewski G
J Gen Virol; 2004 Jun; 85(Pt 6):1419-1426. PubMed ID: 15166424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
